HC Wainwright Reiterates "Neutral" Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA - Get Free Report)'s stock had its "neutral" rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright's price target suggests a potential upside of 5.93% from the stock's current price.

ZURA has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partners began coverage on Zura Bio in a research report on Monday, November 4th. They set an "outperform" rating and a $15.00 target price for the company. Piper Sandler reaffirmed an "overweight" rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partnrs raised Zura Bio to a "strong-buy" rating in a research report on Monday, November 4th. Finally, Chardan Capital decreased their target price on Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zura Bio has a consensus rating of "Buy" and an average price target of $15.80.

Zura Bio Price Performance

ZURA traded up $0.14 during trading hours on Monday, reaching $4.72. 229,922 shares of the company's stock traded hands, compared to its average volume of 326,218. The firm has a 50-day moving average price of $4.19 and a 200 day moving average price of $4.12. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). As a group, sell-side analysts anticipate that Zura Bio will post -0.49 EPS for the current year.

Insider Transactions at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the business's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.10% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ZURA. Affinity Asset Advisors LLC acquired a new position in Zura Bio during the 1st quarter valued at about $1,157,000. Bank of New York Mellon Corp increased its position in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock valued at $165,000 after buying an additional 6,412 shares in the last quarter. Renaissance Technologies LLC increased its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after buying an additional 5,900 shares in the last quarter. Great Point Partners LLC increased its position in Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock valued at $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Finally, Armistice Capital LLC increased its position in Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after buying an additional 876,000 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.